Specifically, the IGF2BP1 altered group exhibited a greater incidence of HER2 mRNA gain (Figure 1D), higher proportion of HER2 and luminal B subtypes by prediction analysis of microarray 50 (PAM50) (Figure 1E) or HER2 and ER+/HER2- with high proliferating subtypes by three genes classifiers (Figure 1F), a tendancy to manifest, grade-3 histology (Figure 1G), higher clinical tumor stages (Figure 1H), and an increased probability of disease-specific death (Figure 1I). The gene discussed is ERBB2; the disease is neoplasm.